Page 7 - Guidelines Panel News Today

Previously, Robert Califf previewed his priorities, if confirmed, to the Senate HELP Committee.

A daily roundup of news on COVID-19 and the rest of medicine

A combination of remdesivir and a concentrated solution of antibodies did not work well in people hospitalized with COVID-19, ...

WASHINGTON (dpa-AFX) - The U.S. Food and Drug Administration has revised the authorizations for two monoclonal antibody treatments - bamlanivimab and etesevimab (administered together) and REGEN-COV

The U.S. Food and Drug Administration has subtracted a pair of COVID-19 monoclonal antibody treatments from the approved list due to what the agency has deemed "ineffectiveness" against the Omicron variant, which has spread rapidly throughout the U.S. and the world. Bamlanivimab and etesevimab, which are administered in tandem, and REGEN-COV are no longer authorized for use,

Doctors who have developed effective protocols treating COVID-19 patients have difficulty getting their voices heard because information has been suppressed

The U.S. Food and Drug Administration (FDA) announced Jan. 24 it is restricting the use of two monoclonal ...

(The Center Square) – The Food and Drug Administration announced Monday evening that effective immediately, certain monoclonal antibodies would no longer be available to states and health-care providers, saying they

Bamlanivimab/etesevimab and casirivimab/imdevimab are highly unlikely to be active against the Omicron variant, which now makes up virtually all cases of COVID-19 in the United States, the FDA says.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero